Abstract
Personalized Medicine: The impact of proteomics on drug discovery and
clinical trial design is a management report that analyses how proteomics will
streamline drug development and lead to the more cost-effective development of
niche personalized products of the future.
Proteomics promises lower R&D costs and the opportunities of new revenue
streams through the identification of new drug targets in the treatment of
diseases such as cancer and Alzheimers. Use this report to identify the most
important technologies, their applications in drug discovery and clinical trial
design and the leading companies driving development of this exciting new area.
The pharmaceutical industry has so far been slow to take up proteomic
technology and strategic alliances and acquisitions will be central to the
pharmaceutical industrys uptake of proteomics. This report identifies the key
technologies that will enable pharmaceutical companies to develop new niche
products, improve drug attrition rates, increase the speed of clinical
development and target new drug markets.
Key findings of the report
Proteomics has the potential to reduce drug development time and drug
attrition rates. If total development time is reduced by three years and the
number of successful NDAs doubled, R&D costs could be cut by as much as 30%
per year. Companies investing in proteomics to target niche markets can reap
considerable financial rewards as exemplified by Gleevec (Novartis) and
Herceptin (Roche) which generated around $1bn in worldwide sales in 2003. There
is a high unmet clinical need for early disease detection, such as in cancer and
neurodegenerative diseases. The development of diagnostic tools using
"biomarkers" has the potential to result in better prognosis for
patients and to satisfy this unmet need. More that $700m has been invested in
proteomics companies by venture capitalists and through IPOs (Initial Public
Offerings) in the last four years. As the main bottleneck in proteomics is the
ability to analyze the colossal amount of data generated, it is essential for
companies to invest heavily in bioinformatics.
View Cart
